Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9548691 | 0.92 | TK1 (0.46) | TOP2ATK1 | |
| SCHEMBL9548698 | 0.92 | TK1 (0.46) | TOP2ATK1 | |
| SCHEMBL12942600 | 0.92 | TK1 (0.46) | TOP2ATK1 | |
| SCHEMBL9548643 | 0.88 | TK1 (0.45) | TOP2ATK1 | |
| SCHEMBL8932095 | 0.88 | TOP2A (0.43) | TOP2ATK1 | |
| SCHEMBL25400182 | 0.88 | TK1 (0.45) | TOP2ATK1 | |
| SCHEMBL26274379 | 0.88 | TK1 (0.45) | TOP2ATK1 | |
| SCHEMBL9548639 | 0.88 | TK1 (0.45) | TOP2ATK1 | |
| SCHEMBL26277360 | 0.85 | DUT (0.40) | — | |
| SCHEMBL25402005 | 0.85 | DUT (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298783-B1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | UNIV YALE (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9126971-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8193165-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2298783-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | Yale University (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-25 | — | — | US | disclosed |
| US-7589078-B2 | Using a dideoxy and didehydro nucleoside | YALE UNIVERSITY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048500-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | TYMP, ITPA, SAMHD1 | TOP2A 144/4885TK1 91/4885 |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | TYMP, ITPA, SAMHD1 | TOP2A 144/4885TK1 91/4885 |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | CCR1, CCR4, CCR3 | TOP2A 1228/4885TK1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.